FOR IMMEDIATE RELEASE: Australian Distributor Receives Largest Tender Ever Granted in Aussie Mining Industry KINDERHOOK, NY -- January 22, 2024 -- American Bio Medica Corp. (NASDAQ: ABMC) announced today that its Australian distributor, The Frontline Diagnostics Co., a company who's core business is the detection of drugs and the protection of workers, is the recipient of a tender valued at more than $500,000. This tender is the largest ever granted in the Australian mining industry for drug screening and will exclusively use the patented Rapid Drug Screen for on-site testing of its workers. American Bio Medica's distributor, Frontline Diagnostics, will be traveling to different mining sites in mobile onsite clinics, to perform drug-screening services using the Rapid Drug Screen, ABMC's on-site single-step test that provides positive or negative results within 5 minutes for each substance being screened. The test administrator does not need to add reagents, use a pipette to transfer the urine sample, or mix, tilt or stir the mixture, which is necessary with the majority of drug tests currently available thus making it ideal for use in the mobile units. Frontline plans to have 6 mobile clinics operating in the first year of the contract. Michael White, Frontline Diagnostics Managing Director, stated "It was vital to us to win this contract as we could see that the rest of the mining industry, and the contractors who service them would fall in line to ensure their drug & alcohol management systems were as good if not better than one of the world's biggest players. This will ensure enormous growth for us and this is something we can share with our manufacturers. We believe that the contract was won by us demonstrating exceedingly high levels of service using the best drug screening product available, the ABMC Rapid Drug Screen." American Bio Medica Corporation develops, manufactures and markets inexpensive, accurate on-site drugs-of-abuse diagnostic kits, sprays and support services worldwide. The company's global distributors target the workplace, physicians, corrections, clinical and educational markets. ABMC's Drug Detector identifies minute traces of illegal drugs on surfaces, while the company's Rapid Drug Screen tests individuals and is proven to correlate greater than 99% with the standard laboratory screening test. Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risk and uncertainties, including without limitation, continued acceptance of the Company's products, increased levels of competition for the Company, new products and technological changes, the Company's dependence on third-party suppliers, intellectual property rights and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission. Contact: American Bio Medica Corporation Melissa A. Decker Manager Investor Relations & Corporate Communications Tel: (800) 227-1243 Fax: (518) 758-8171 Email: melissa@americanbiomedica.com Web: www.americanbiomedica.com |